This study investigates the effects of an investigational medication on low-grade gliomas in children with Neurofibromatosis 1. Neurofibromatosis 1 is a genetic disorder that often causes benign tumors on nerve tissue, which can sometimes develop into low-grade gliomas, a type of brain tumor. The purpose of this study is to see if the investigational medication can shrink or slow the growth of these tumors.
Participants will receive the investigational medication and will be monitored for changes in tumor size and growth. The study involves regular medical assessments to evaluate the effects of the treatment on the gliomas.
- Who can participate: Children aged 5-18 years diagnosed with Neurofibromatosis 1 and low-grade gliomas are eligible to participate.
- Study details: Participants will take the investigational medication and undergo regular assessments to monitor tumor response. A placebo is not used in this study.
